.

Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Evaluate market entry opportunities
  • Find generic sources and suppliers
  • Predict branded drug patent expiration

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Details for Patent: 5,583,129

« Back to Dashboard

Details for Patent: 5,583,129

Title: Composition for contraception
Abstract:This invention relates to a method of inducing contraception comprising administering an estrogen selected from 2.0 to 6.0 mg of 17.beta.-estradiol and 0.015 to 0.020 mg of ethinylestradiol; and a gestagen selected from 0.05 to 0.075 mg of gestodene, 0.075 to 0.125 mg of levonorgestrel, 0.06 to 0.15 mg of desogestrel, 0.06 to 0.15 mg of 3-ketodesogestrel, 0.1 to 0.3 mg of drospirenone, 0.1 to 0.2 mg of cyproterone acetate, 0.2 to 0.3 mg of norgestimate and >0.35 to 0.75 mg of norethisterone for a female of reproductive age, who has not yet reached premenopause, by administration for 23 or 24 days, beginning on day one of the menstrual cycle, followed by 5 or 4 pill-free or sugar pill days, during a total of 28 days in the administration cycle.
Inventor(s): Spona; J urgen (A-1190 Vienna, AT), D usterberg; Bernd (D-12307 Berlin, DE), L udicke; Frank (CH-1211 Geneva 4, CH)
Assignee:
Filing Date:Jun 30, 1994
Application Number:08/268,996
Claims:1. A method of inducing contraception in a female of reproductive age who has not yet reached premenopause, comprising administering to said female a composition comprising an estrogen selected from

2.0 to 6.0 mg of 17.beta.-estradiol and

0.015 to 0.020 mg of ethinylestradiol;

and a gestagen selected from

0.05 to 0.075 mg of gestodene,

0.075 to 0.125 mg of levonorgestrel,

0.06 to 0.15 mg of desogestrel,

0.06 to 0.15 mg of 3-ketodesogestrel,

0.1 to 0.3 mg of drospirenone,

0.1 to 0.2 mg of cyproterone acetate,

0.2 to 0.3 mg of norgestimate and

>0.35 to 0.75 mg of norethisterone;

wherein the composition is administered for 23 or 24 days, beginning on day one of the menstrual cycle, followed by 5 or 4 pill-free or sugar pill days, during a total of 28 days in the administration cycle.

2. A method according to claim 1, whereby the estrogen is ethinylestradiol.

3. A method according to claim 1, whereby the estrogen is 17.beta.-estradiol.

4. A method according to claim 1, whereby the gestagen is gestodene.

5. A method according to claim 1, whereby the gestagen is levonorgestrel.

6. A method according to claim 1, whereby the gestagen is cyproterone acetate or drospirenone.

7. A method according to claim 1, whereby the composition comprises an estrogen selected from

>2.0 to 6.0 mg of 17.beta.-estradiol and

0.020 mg of ethinylestradiol;

and a gestagen selected from

>0.06 to 0.075 mg of gestodene,

>0.100 to 0.125 mg of levonorgestrel,

>0.10 to 0.15 mg of desogestrel,

>0.10 to 0.15 mg of 3-ketodesogestrel,

0.25 to 0.30 mg of drospirenone,

0.1 to 0.2 mg of cyproterone acetate,

0.2 to 0.3 mg of norgestimate and

0.50 to 0.75 mg of norethisterone.

8. A method according to claim 1, whereby the estrogen is present in a dose of 20 .mu.g of ethinylestradiol or an equivalent dose of 17.beta.-estradiol and the gestagen is present in a dose of 75 .mu.g of gestodene or an equivalent dose of levonorgestrel, cyproterone acetate or drospirenone.
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

How are People Using DrugPatentWatch?

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc